Navigation Links
Amarantus BioSciences Issues CEO Letter to Shareholders
Date:11/19/2012

SUNNYVALE, Calif., Nov. 19, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong issued a letter to shareholders as detailed below.

Dear Shareholders,

I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.

As was recently announced, we were able to strengthen the corporation's balance sheet by raising cash and reducing liabilities. These financing transactions were vital for the Company to pay certain vendors who are critical to on-going operations, as well as raise sufficient working capital to pursue our corporate strategy, as detailed below. Our management team and Board of Directors remain extremely dedicated to the overall success of the corporation. This is evidenced by every member working without cash consideration since Amarantus became public in the spring of 2011. This has allowed all available resources to be focused on product development.

With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investor
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amarantus BioSciences Secures $1.1 Million in Financing
2. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
3. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
6. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
7. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
8. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... (PRWEB) November 23, 2014 One of the ... of optics and photonics is now available to high school ... low cost. SPIE, the international society for optics and ... the complete SPIE Digital Library available to high ... , “Light-based technologies are integral to all areas of life ...
(Date:11/24/2014)... Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. ... both in the United States District Court for ... . On November 21, 2014 ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 During his ... understood the need to surround himself with great people ... and entrepreneur, his friends often marveled at his extraordinarily ... lived his life and -- even with his death ... the Alzheimer’s disease that would ultimately take his life. ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed ... Technologies Summit in San Francisco to take first place ... Silicon Valley investors and technology elites as the premier ... positions Briteseed to move on to the final ... compete with other elite innovation finalists for a $125,000 ...
Breaking Biology Technology:SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... Research & Development Team, CLINTON, N.J., ... fully,integrated critical care biotherapeutics company, announced that ... President of Translational,Medicine, reporting to Ralf Rosskamp, ... of Ikaria., As Vice President of ...
... Thursday, June 26th at 2:30pm ET, NEW YORK, ... today announced that Michael S. Weiss, the Company,s,Chairman and ... & Co. Healthcare Conference being held in New York ... on Thursday, June 26th at,2:30pm ET and will be ...
... New Generation Biofuels,Holdings, Inc. (AMEX: GNB ), a ... Exchange (AMEX) in mid-April, will join the Russell,Microcap Index ... Friday, June 27th, after the market closes, according to ... ., Membership in the Russell Microcap Index, which ...
Cached Biology Technology:Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine 2Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine 3Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference 2New Generation Biofuels Set to Join Russell Microcap Index 2New Generation Biofuels Set to Join Russell Microcap Index 3
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
(Date:11/2/2014)... put a flashlight up to our palms to see ... St. Louis engineers are using a similar idea to ... of cancerous tissues and to develop potential treatments. ... Professor of Biomedical Engineering at the School of Engineering ... that allows researchers to better focus light in tissue, ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... 2008) Argonne National Laboratory has signed a ... Laboratory (SRNL) to collaborate on nuclear energy and ... U.S. Energy Department (DOE) needs and other important ... remain a leader in nuclear energy research," Argonne ...
... the molecule hydroxyl on another planet for the first ... to unlock the workings of Venuss dense atmosphere. ... of a hydrogen and oxygen atom each. It has ... atmosphere, some 100 km above the surface, by Venus ...
... tea may be able to stave off the cognitive ... to a new study published in the second issue ... of Respiratory and Critical Care Medicine. Researchers examined ... water, on rats who were intermittently deprived of oxygen ...
Cached Biology News:Argonne-SRNL agreement supports critical DOE, national priorities 2Key molecule discovered in Venus's atmosphere 2Green tea compounds beat OSA-related brain deficits 2
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Biology Products: